The impact of inhalation anesthetics on early postoperative cognitive function and recovery characteristics in Down syndrome patients: a randomized, double–blind study

Emmanouil Gkliatis1, Alexandros Makris1* and Chryssoula Staikou2

Abstract

Background: Down syndrome (DS) is associated with intellectual disability. DS patients may be unable to cooperate and often require general anesthesia even for minor surgeries. Rapid recovery significantly contributes to fast-tracking. This prospective randomized, double - blind study investigates the impact of desflurane and sevoflurane on recovery and early postoperative cognitive function of these patients.

Methods: Forty-four patients undergoing dental surgery, were randomized to receive desflurane (DES-group) or sevoflurane (SEVO-group) for anesthesia maintenance. The primary outcome was postoperative cognitive function (Prudhoe Cognitive Function Test, PCFT) at 90 min and 4 h postoperatively. Secondary outcome measures were the time between volatile discontinuation and spontaneous breath, eye opening, extubation, orientation and response to commands, time to achieve an Aldrete score ≥ 9 in the Post-anesthesia Care Unit and time to fulfill discharge criteria (Post Anesthetic Discharge Scoring System, PADSS).

Results: At 90 min, PCFT scores significantly decreased from baseline in both groups. Nevertheless, at 4 h, in DES-group there was no significant change from baseline (p = 0.163), while in SEVO-group the decrease remained significant (p < 0.001). Desflurane was also found superior regarding recovery characteristics, such as time to eye opening (p = 0.021), spatial orientation (p = 0.004), response to commands (p = 0.004). Discharge criteria were met earlier in DES-group (p = 0.018 for Aldrete score / p < 0.001 for PADSS).

Conclusions: Desflurane was found superior to sevoflurane in terms of faster recovery and better preserved postoperative cognitive function in DS patients undergoing dental surgery. We suggest that desflurane, as part of a multimodal anesthetic approach, could be a useful agent to enhance early discharge from hospital of ambulatory patients with intellectual disability.

Trial registration: Registered with ClinicalTrials.gov (NCT02971254, principal investigator: E.G; November 2016).

Keywords: Sevoflurane, Desflurane, Down syndrome, Anesthesia

Background
Down syndrome (DS) is the most common chromosomal abnormality in humans, caused by the presence of a full or partial third copy of chromosome 21. It is associated with a variety of birth defects and diseases, including developmental, neurological and neurotransmitter alterations,

© The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
intellectual disability (ID) and increased occurrence of Alzheimer’s disease. The improvement in medical care over the years has significantly increased the life expectancy of individuals with DS, and survival into adulthood is now reasonably expected [1].

The DS is the commonest genetic cause of ID that represents a constant and characteristic feature of the syndrome [2]. The degree of ID varies significantly among people with DS, ranging from mild to moderate or severe. However, most commonly it falls within the mild to moderate range [3]. These patients may be unable to comprehend the purpose of any medical intervention and it is difficult to cooperate even for minor surgical procedures. Within this context, dental treatment for DS patients with ID is often performed under day care general anesthesia.

On the other hand, anesthetic drugs may transiently impair patients’ cognitive function and mental status postoperatively, thus delaying their discharge from hospital, especially in case day surgery. Rapid recovery from anesthesia significantly contributes to fast-tracking through postoperative recovery steps and discharge, increases patient comfort and satisfaction, while reducing financial costs and nursing workload in ambulatory care settings [4].

Volatile anesthetics with low blood-gas partition coefficients, such as desflurane and sevoflurane, may be associated with less postoperative cognitive impairment and confusion. There are several studies comparing the two volatiles regarding their recovery characteristics and effects on postoperative cognition. Still, they are mainly focused on elderly population and present contradictory results, favoring none of the two or slightly favoring desflurane [5–14]. To our knowledge the present study is the first to examine the impact of the two most popular volatile anesthetics, namely desflurane and sevoflurane, on recovery and early postoperative cognitive function of patients with preexisting ID, specifically adult DS patients.

Methods

The present randomized, double-blind, parallel-group study was approved by the Institutional Review Board of the Asklepieion Hospital of Voula (identification number: 8174/2016) and was registered with ClinicalTrials.gov (NCT02971254, principal investigator: E.G; Date of Registration: 22/11/2016). Inclusion criteria were Down syndrome patients scheduled for dental surgery, age above 14 years and American Society of Anesthesiologists (ASA) classification I - III. Exclusion criteria were severe visual or hearing impairment and severe dementia, characterized as inability or showing difficulty to communicate. A written informed consent was obtained from all participants’ caretakers (parents or legal surrogates). The Consort Guidelines for reporting Randomized Controlled Trials were followed for the presentation of the study.

Fifty-seven consecutive DS patients were assessed and those found eligible for inclusion were randomly assigned to receive either desflurane (DES-group, n = 22) or sevoflurane (SEVO-group, n = 22) for maintenance of anesthesia, according to a computer generated list. Randomization was performed using the study randomization engine created by Urbaniak, G. C., & Plous, S. in 2013 [Research Randomizer (Version 4.0) (Computer software, retrieved on June 22, 2013, from http://www.randomizer.org/)].

The primary outcome measure was the early postoperative cognitive function, as assessed with the Prudhoe Cognitive Function Test (PCFT) which is designed to “quantitatively” measure cognitive function in people with any degree of ID. It was initially designed to establish a baseline of pre-existing cognitive functioning in adults with DS [15]. It assesses competencies in five areas, Orientation (checking if the participant is oriented temporally - comparing events in relationship to when they occur), Recall (checking memory skills), Language (a test of verbal expression - not of knowledge), Praxis (assessing ability of the participant to demonstrate adequately how to carry out the appropriate actions) and Calculation (counting) [15–17]. It is simple and takes a maximum of 20 min to complete. It consists of 84 items and has a maximum overall score of 240 points. A score below 128 indicates a severe ID [15]. It is sensitive in identifying cognitive decline over time and this is the reason it was considered appropriate for the aim of this study, dealing with cognitive changes over time perioperatively. Patients’ screening and the test were performed in the hospital ward. The environment for the test was kept quiet with only one familiar person to the patient in the room and removal of any stimuli that could be distracting.

In the operating room a 20-gauge intravenous (IV) cannula was inserted for fluid and drug administration. Monitoring included electrocardiogram, pulse oximetry, noninvasive blood pressure, capnography and neuromuscular transmission (NMT) monitoring (TOF-Scan®; IDMed; Marseille, France). Prior to anesthesia induction, ondansetron 4 mg, metoclopramide 10 mg, dexamethasone 4 mg for prevention of postoperative nausea/vomiting (PONV) and paracetamol 1000 mg for pre-emptive analgesia were administered IV. General anesthesia was induced with fentanyl 50 mcg, propofol 2.5 mg/kg and rocuronium 0.9 mg/kg for facilitation of tracheal intubation. Anesthesia was maintained with desflurane (DES-group) or sevoflurane (SEVO-group)
in an oxygen/air mixture (FiO₂: 0.4, total fresh gas flow rate: 1.5 L/min). The administered volatiles were adjusted to target a minimum alveolar concentration (MAC) of 1, modified for age. Ventilation was controlled to maintain normocarbia (End tidal CO₂, ETCO₂: 35–40 mmHg).

At the end of surgery, following the last surgical manipulation, the volatile agent was discontinued, total fresh gas flow rate was increased to 8L/min, FiO₂ was increased to 1.0 and residual neuromuscular blockade was reversed with sugammadex. Extubation was attempted when the NMT’s train-of-four (TOF) ratio was 0.9 and sufficient spontaneous breathing in an awake patient was achieved.

Afterwards, all patients were transferred to the post-anesthesia care unit (PACU), where standard monitoring was applied. Patients were discharged from the PACU to the ward with a modified Aldrete score of 9 or 10 [18]. In case post-operative analgesia was required, parecoxib 40mg was administered. Ondansetron 4mg was used to treat PONV. Patients were considered ready to be discharged home when they had a Post-Anesthesia Discharge Scoring System (PADSS) score of 9 or more [19]. The PADSS is used for outpatients and includes the following 6 criteria, which are scored from 0 to 2: vital signs, ambulation, PONV, pain, bleeding and voiding. A score of 9 or 10 is considered safe for outpatients to be discharged from hospital [19].

During anesthesia, the following data were recorded: systolic, diastolic, and mean arterial pressure (SAP, DAP, and MAP, respectively), heart rate (HR), ETCO₂, hemoglobin saturation (SpO₂), inhaled and exhaled volatile anesthetic concentration and MAC values.

The secondary outcome measures were related to recovery characteristics. We measured the time between discontinuation of the volatile agent and first spontaneous breath, first eye opening, extubation, orientation in place and first responding to verbal commands. Also, the time of fulfillment of the criteria to discharge from PACU (Aldrete score ≥ 9), orientation in place, time and person in the PACU, postoperative need for antiemetics and analgesics were recorded. Additionally, the caretaker was asked to assess him/herself the patient’s alertness (1 point for sleepy, 2 points for tired, 3 points for awake), wellness (1 point for poor, 2 points for moderate, 3 points for good, 4 points for excellent) and energy (1 point for poor, 2 points for moderate, 3 points for normal), pre-operatively and also at 90min and 4h postoperatively. Satisfaction from anesthetic handling reported by the caretakers was recorded as well, using a 0 to 10 scale (0 for the worst and 10 for the highest possible satisfaction). Finally, the time of fulfillment of the criteria of PADSS were recorded.

The study is double-blind as neither the patients and caretakers nor the investigators who were involved in the primary and secondary outcome measures (PCFT and recovery characteristics) where aware of the patient group allocation. Regarding recovery characteristics recorded in the operating theatre, a blinded observer was entering the room after discontinuation of the volatile agent and after covering the relevant area on the monitor.

### Statistical analysis

The methodology of power analysis represented a design, with two levels of the between-subject factor of the two study groups and three levels of the within-subjects factor of time. A repeated measures analysis of variance (ANOVA) power analysis was conducted. The power calculation was performed a-priori, based on effect sizes of mean differences that we could detect at every quantitative measure of the study. The effect size for this calculation used the ratio of the standard deviation of the effects for a particular factor or interaction and the standard deviation of within-subject effects. The power analysis was conducted for a single, two-group between-subjects factor, and a single within-subjects factor assessed over three time points. For this design, 44 participants (22 per group) achieves a power of 0.90 for the within-subjects main effect at an effect size of 0.20; a power of 0.90 for the between-subjects main effect at an effect size of 0.36; and a power of 0.90 for the interaction effect at an effect size of 0.22.

Continuous variables are presented with mean and standard deviation (SD) and/or with median and interquartile range (IQR). Quantitative variables are presented with absolute and relative frequencies. For the comparison of proportions chi-square tests were used. For the comparison of continuous variables between the two study groups, the Student’s t-test was computed in case of normal distribution and the Mann-Whitney test in case of not normal distribution. Differences in changes of PCFT, Alertness, Wellness and Patient Energy during the follow up period between the two study groups were evaluated using repeated measurements ANOVA. Variables that had skewed distribution were log-transformed for the analysis of variance. All p values reported are two-tailed. Statistical significance was set at 0.05 and analyses were conducted using SPSS statistical software (version 22.0).

### Results

Data from 43 patients (22 in the DES-group, 21 in the SEVO-group) were analyzed, in a 24months period, as shown in the flow diagram of the study (Fig. 1). The demographic and operative characteristics of the patients were similar between the two groups (Table 1).
The recorded PCFT scores of the study groups during the follow up period (preoperatively-baseline, at 90 min and at 4 h) are presented in Table 2. The baseline of the total PCFT scores -along with its five domains individually (Orientation, Recall, Language, Praxis and Calculation)- did not differ statistically between the DES and SEVO-group. Intragroup comparisons showed that 90 min after recovery, total PCFT scores,
Orientation, Language, Praxis and Calculation domain scores decreased significantly from baseline in both groups. Recall decreased significantly only in the SEVO-group. Intergroup comparisons showed that total PCFT scores and Orientation, Language, Praxis and Calculation domain scores were significantly higher in the DES versus SEVO-group ($p < 0.05$). Four (4) hours after recovery, total PCFT scores, Orientation, Recall, Language and Praxis domain scores reached levels similar to baseline scores in the DES-group, while in the SEVO-group they remained significantly lower. The scores in the Calculation domain did not differ significantly between the two groups. The overall change of total PCFT scores and all domains with the exception of Orientation and Calculation, during the follow up was significantly different between the two groups as indicated from the significant interaction effect of the analyses ($P_3$ in Table 2).

Patients’ alertness, wellness and energy were restored to their preoperative values at 90min in the DES-group while in the SEVO-group they remained significantly reduced compared to baseline. In the SEVO-group alertness and wellness were restored at 4h, but energy remained reduced, even though the statistical significance was marginal ($p=0.049$ for comparison with baseline), as shown in Table 3.

Time to first eye opening, time to orientation in place, time to first responding to verbal commands, time to reach modified Aldrete score ≥ 9 in PACU and time to fulfill discharge criteria (PADSS) were significantly shorter in the DES-group as compared to SEVO-group. Time to first spontaneous breath and extubation did not differ significantly between the groups (Table 4). No additional need for antiemetics and analgesics was recorded.

Regarding intraoperative parameters, there was no statistically significant difference between the groups ($p > 0.05$) in baseline values, overall mean SAP, DAP and MAP. Mixed-effects linear regression analysis to check if measurements changed differently between groups, showed no significant change in SAP, DAP and MAP in either group. There was no statistically significant difference between groups in baseline HR and overall mean HR ($p > 0.05$). Mixed-effects linear regression analysis showed a significant decrease in HR during measurement period in both groups, which was less in the DES-group. There was no statistically significant difference between groups in baseline and overall mean SpO2 and ETCO2 ($p > 0.05$).

### Table 2 Changes in PCFT during the follow up for the two study groups (Desflurane group: DES-group and Sevoflurane group: SEVO-group)

| Group   | Baseline | 90′ after recovery | 4h after recovery | $P_2$ Baseline vs 90′ | $P_2$ Baseline vs 4h | $P_2$ 90′ vs 4h | $P_3$ |
|---------|----------|--------------------|-------------------|-----------------------|----------------------|-----------------|-------|
| DES     | 137 (54.6) | 125.6 (52.5)      | 133.4 (53.1)      | <0.001*               | 0.163                | <0.001*         | <0.001*|
| SEVO    | 111.57 (55.47) | 78.76 (52.41)       | 94 (53.97)        | <0.001*               | <0.001*               | <0.001*         | <0.001*|
| $P_1$   | 0.138  | 0.006*            | 0.021*            |
| Orientation | 11.7 (4.9) | 10.5 (4.9)       | 11.6 (5)           | 0.033*               | 1.000*               | 0.006*          | 0.073 |
| SEVO    | 8.96 (3.82) | 6.67 (3.23)       | 7.95 (3.2)         | <0.001*               | 0.018*               | 0.006*          | 0.001*|
| $P_1$   | 0.054  | 0.004*            | 0.006*            |
| Recall  | 10.3 (5.4) | 10 (5.5)        | 10.4 (5.3)         | 1.000                 | 1.000                 | 0.986           | 0.033*|
| SEVO    | 10.67 (4.62) | 7.52 (4.09)       | 9.14 (3.88)        | <0.001*               | 0.017*               | 0.006*          | 0.001*|
| $P_1$   | 0.799  | 0.102             | 0.397             |
| Language | 59.5 (20) | 54.6 (20.7)       | 58.6 (20.9)        | 0.005*               | 1.000                 | 0.003*          | 0.001*|
| SEVO    | 48.19 (23.53) | 35.14 (26.27)     | 41.19 (25.1)       | <0.001*               | <0.001*               | <0.001*         | <0.001*|
| $P_1$   | 0.098  | 0.010*            | 0.018*            |
| Praxis  | 41.1 (18.9) | 36.9 (16.6)       | 39.9 (17.9)        | 0.016*               | 0.521                 | 0.012*          | <0.001*|
| Group   | 34.19 (21.8) | 22.48 (17.53)     | 27.62 (19.14)      | <0.001*               | <0.001*               | <0.001*         | <0.001*|
| $P_1$   | 0.273  | 0.008*            | 0.036*            |
| Calculation | 14.4 (12.7) | 12.4 (10.7)       | 12.9 (10.6)        | 0.034*               | 0.056                 | 0.656           | 0.646 |
| SEVO    | 9.19 (7.48) | 6.95 (6.05)       | 8.1 (6.46)         | 0.021*               | 0.263                 | 0.043*          | 0.082 |
| $P_1$   | 0.110  | 0.049*            | 0.082             |

PCFT Prudhoe Cognitive Function Test. Data are presented as mean (SD); * indicates statistical significance ($p < 0.05$); $P_1$: $P$-value for group effect; $P_2$: $P$-value for time effect; $P_3$: Effects reported include differences between the groups in the degree of change (repeated measurements ANOVA).
Finally, desflurane was associated with a superior overall patient experience. Satisfaction score in the DES-group had a mean equal to 9.8 (SD = 0.5) and median 10 (IQR: 10–10), while satisfaction score in the SEVO-group was significantly lower, with a mean equal to 9.1 (SD = 1.2) and median 9 (IQR: 9–10), (Mann Whitney test, \( p = 0.008 \)).

**Discussion**

The present study investigated the impact of the two most popular volatiles, desflurane and sevoflurane, on postoperative cognitive function and recovery characteristics in DS population. Regarding the primary outcome, our results demonstrated that early postoperative cognitive function scores were higher when anesthesia was maintained with desflurane. The difference was more apparent 90 min after recovery, but remained significant for at least 4 h. Most importantly, 4 h after recovery, there was no significant change from baseline in DES-group while in SEVO-group the difference from the preoperative baseline remained statistically significant. Desflurane was also found superior in terms of recovery times. Finally, the discharge criteria from both PACU and hospital were fulfilled earlier when desflurane was used. The favorable recovery characteristics of desflurane identified by our study can be mainly attributed to its low solubility in blood and body tissues (blood: gas partition coefficient of 0.42 and fat: blood solubility 27 at 37 °C) compared to sevoflurane (blood: gas partition coefficient of 0.65 and fat: blood solubility 48 at 37 °C) [20].

Various studies have investigated the impact of anesthetic agents on recovery and postoperative cognition, but it is difficult to compare our findings to theirs, since most of them were performed in elderly patient populations and have different methodologies, mainly using the Mini-Mental State Examination (MMSE) [5–14]. Additionally, they mostly focus on postoperative delirium in older age groups and postoperative cognitive dysfunction (POCD) that appears after patient discharge. Among these studies, those which focused on recovery characteristics, suggest that desflurane is superior [6, 8, 13] or comparable to sevoflurane [10, 11]. Similarly, studies focused on cognitive function, find desflurane slightly superior [7, 8, 12] or equivalent to sevoflurane [5, 9, 10, 14]. To our knowledge there are no studies investigating early recovery and cognitive characteristics in younger patients with DS or any intellectual disability.

On a first read, a difference in the PCFT scores between the two anesthetic groups at 90 min and 4 h after surgery, as well as the recovery characteristics, could seem...
unlikely to be clinically significant. On the contrary, we consider that in this patient population these parameters may be of major clinical significance. In the PACU or other recovery units, patients with intellectual disabilities show several problems. The personnel in these units are usually limited and have to take care of more than one patient. This could lead to deficits in the special care that most DS patients might need, since close observation is essential until they are fully recovered from anesthesia, and even afterwards. Moreover, patients with ID are also at higher risk for inadequate analgesia due to their limited capacity to express verbally or behaviorally their pain or other unpleasant feelings. Occasionally they feel excessive discomfort. Unrelieved pain, stress and fear may further exacerbate their cognitive impairment [21]. Their limited communication skills and the presence of maladaptive behaviors may cause distress to them and their caretakers [22–25]. Thus, it is imperative to use aesthetic techniques that may ensure the earliest return of cognitive function possible, so that this sensitive patient population may express their feelings and get adequate relief of their pain, distress and fear.

Patients’ alertness, wellness and energy were assessed by the caretakers. This could render assessment subjective but on the contrary, these results provide more valuable and accurate data regarding caretakers’ satisfaction grade and confidence to the aesthetic technique and patient safety. Higher scores mean that caretakers feel more comfortable and sure that fast-tracking will not jeopardize patients’ safety.

The use of appropriate drugs and aesthetic techniques may allow the phase of early recovery to be complete before the transfer to PACU, and some patients can bypass the first stage recovery (patient is awake, protective airway reflexes have returned, pain is controlled) [4, 26]. The second-stage recovery follows, ending when patients are ready for hospital discharge [4]. Even mild postoperative cognitive dysfunction and discomfort may delay this stage and prolong hospital stay. The latter may have a negative impact on patients’ and caretakers’ satisfaction, but most importantly it may increase the risk of hospital-acquired infections, especially in DS patients who are more susceptible due to dysfunction of the cellular and humoral immunity [4, 27]. There is a major effort worldwide to promote day surgery and despite the fact that guidelines are published, ongoing studies explore techniques and pathways to ensure that day surgery is applied to more patient groups. The need to minimize length of stay and improve the quality of postoperative recovery have ensured that day surgery principles are fundamental to modern patient care. Our study suggests that desflurane fits better as a maintenance agent for these cases.

One of the main strengths of our study is the homogeneity of the sample, that is DS patients with similar phenotypes and pathophysiology of ID. It was challenging and time consuming to gather the required number of unique DS patients. Another advantage is the use of PCFT test which has been specifically constructed to assess the cognitive function in patients with ID of any degree. It is simple and can be carried out by non-specialist evaluators. It is considered highly reliable, since it is given directly to the individual concerned and is not based on information provided by others [15, 16].

There are some limitations to this study. Patients were followed up for the study outcomes until they were discharged from hospital and not afterwards. Nevertheless the caretakers were instructed to call in case of any complication or question. There was no any phone call recorded. Also, they were not screened for the development of delirium, that is an outcome measure of several studies. But even if we did not use a delirium-dedicated scale like Nursing Delirium Screening Scale (NuDESC) or Confusion Assessment Method (CAM), delirium could be suspected indirectly through the patients’ performance on the PCFT test. We did not suspect such a case. Moreover, the target age group of delirium is much older than our sample’s age. Another point to note is that individuals with DS present ID of variable degrees, thus affecting the baseline PCFT scores. Nevertheless, the baseline mean values did not differ between groups, while data analysis focused on the change from the baseline and not the actual score numbers in order to overcome the variability in the degree of ID.

Conclusions

Under the present study design, desflurane was found superior to sevoflurane in terms of faster recovery and better preserved postoperative cognitive function in DS patients undergoing dental surgery. Thus, we suggest that desflurane, as part of a multimodal anesthetic approach, could be a useful agent to enhance fast-tracking and early discharge from hospital of ambulatory patients with ID.

Abbreviations

ANOVA: Analysis of variance; ASA: American Society of Anesthesiologists; CAM: Confusion Assessment Method; DAP: Diastolic arterial pressure; DS: Down syndrome; HR: Heart rate; ID: Intellectual disability; IQR: Interquartile range; IV: Intravenous; MAC: Minimum alveolar concentration; MAP: Mean arterial pressure; MMSE: Mini-Mental State Examination; NMT: Neuromuscular transmission; NuDESC: Nursing Delirium Screening Scale; PACU: Post-anesthesia care unit; PADDSS: Post-Anesthesia Discharge Scoring System; PCFT: Prudhoe Cognitive Function Test; POCD: Postoperative cognitive dysfunction; PONV: postoperative nausea/vomiting; SAP: Systolic arterial pressure; SD: Standard deviation; SpO₂: Hemoglobin saturation; TOF: Train-of-four.
Acknowledgements
The authors would like to thank Dr. Anna Koutsoupaiki, Dr. Chryssi Asmatzi and Dr. Argyro Mela – Karamanakou for their valuable contribution and encouragement. Special thanks to Professor of Anesthesiology Dr. Kassiani Theodoraki and Assistant Professor Dr. Akaterini Melemeni for their valuable scientific guidance.

Authors’ contributions
GE helped in writing the original draft, reviewing and editing of the manuscript, interpretation of the data and final approval of the manuscript. MA helped in conceptualization of the study, supervision, methodology, validation, writing, reviewing and editing of the manuscript, interpretation of the data and final approval of the manuscript. SC helped in validation, supervision, writing, reviewing and editing of the manuscript, interpretation of the data and final approval of the manuscript. All authors read and approved the final manuscript.

Funding
The authors received no funding for this study.

Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was approved by the Institutional Review Board of the Asklepieion Hospital of Voula (identification number: 8174/2016). All methods were performed in accordance with the relevant guidelines and regulations. A written informed consent was obtained from all participants’ caretakers.

Consent for publication
Not applicable.

Competing interests
The authors have no competing interests to declare.

Author details
1 Department of Anesthesiology, Asklepieion Hospital of Voula, Vas. Pavlou 1, 16673 Athens, Greece. 2 Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Greece, Athens, Greece.

Received: 16 March 2021 Accepted: 28 August 2021
Published online: 17 September 2021

References
1. O’Leary L, Hughes-McCormack L, Dunn K, Cooper SA. Early death and causes of death of people with Down syndrome: a systematic review. J Appl Res Intellect Disabil. 2018;31:687–708.
2. Kazemi M, Saleh M, Kheirollahi M. Down syndrome: current status, challenges and future perspectives. Int J Mol Cell Med. 2016;5:125–33.
3. Walker SM. Perioperative care of neonates with Down’s syndrome: should it be different? Br J Anaesth. 2012;108:177–9.
4. Bailey CR, Ahuja M, Bartholomew K, Bew S, Forbes L, Lipp A, et al. Guidelines for day-case surgery 2019: guidelines from the Association of Anaesthetists and the British Association of day Surgery. Anaesthesia. 2019;74:778–92.
5. Chen X, Zhao M, White PF, Li S, Tang J, Wender RH, et al. The recovery of cognitive function after general anesthesia in elderly patients: a comparison of desflurane and sevoflurane. Anesth Analg. 2001;93:1489–94.
6. Chen G, Zhou Y, Shi Q, Zhou H. Comparison of early recovery and cognitive function after desflurane and sevoflurane anesthesia in elderly patients: a meta-analysis of randomized controlled trials. J Int Med Res. 2015;43:619–28.
7. Green MS, Green P, Neubert L, Voralu K, Saththasivam P, Mychaskiw G. Recovery following desflurane versus sevoflurane anesthesia for outpatient urologic surgery in elderly females. Anesth Pain Med. 2015;5:22271.
8. Ergönenç J, Ergönenç T, İdin K, Uzun U, Dirik A, Gedikli G, et al. The recovery time of sevoflurane and desflurane and the effects of anesthesia on mental and psychomotor functions and pain. Anesth Essays Res. 2014;8:367–71.
9. Meineke M, Applegate RL, 2nd, Rasmussen T, Anderson D, Azer S, Mehdi-zadeh A, et al. Cognitive dysfunction following desflurane versus sevoflurane general anesthesia in elderly patients: a randomized controlled trial. Med Gas Res. 2014;4:46.
10. Deepak TS, Vadlamani S, Kumar KS, Kemptegowda P. Post-operative cognitive functions after general anesthesia with sevoflurane and desflurane in south Asian elderly. Middle East J Anaesthesiol. 2013;22:143–8.
11. Boogert S, Ou-Young J, Heiberg J, De Steiger R, Richardson M, Williams Z, et al. A randomized trial of desflurane or sevoflurane on postoperative quality of recovery after knee arthroscopy. PLoS One. 2019;14:e022733.
12. Kuzminskate V, Slauzgalyte I, Bukelyte G, Bruzyne G, Kontrimaviciute E. Effects of sevoflurane and desflurane on early cognitive changes after thyroid surgery: interim results. Acta Med Litu. 2019;26:25–30.
13. Wang C, Li L, Xu H, Lv H, Zhang H. Effect of desflurane-remifentanil or sevoflurane-remifentanil on early recovery in elderly patients: a meta-analysis of randomized controlled trials. Pharmacj. 2019;74:201–5.
14. Alalawi R, Yasmeen N. Postoperative cognitive dysfunction in the elderly: a review comparing the effects of Desflurane and Sevflurane. J Perianesth Nurs. 2018;33:732–40.
15. Kay DW, Tyser SP, Margallo-Lana ML, Moore PB, Fletcher R, Berney TP, et al. Preliminary evaluation of a scale to assess cognitive function in adults with Down’s syndrome: the Prudhoe cognitive function test. J Intellect Disabil Res. 2003;47:155–68.
16. Margallo-Lana ML, Moore PB, Tyser SP, Dawson H, Jenkins K, Kay DW. The Prudhoe cognitive function test, a scale to assess cognitive function in adults with Down’s syndrome: inter-rater and test-retest reliability. J Intellect Disabil Res. 2003;47:488–92.
17. Tyser SP, Wigham A, Ciccietti D, Margallo-Lana M, Moore PB, Reid BE. Comparison of short and long versions of the Prudhoe cognitive function test and the K-BIT in participants with intellectual impairment. J Autism Dev Disord. 2010;40:1000–5.
18. Aldrete JA. The post-anesthesia recovery score revisited. J Clin Anesth. 1995;7:89–91.
19. Chung F, Chan VW, Ong D. A post-anesthetic discharge scoring system for home readiness after ambulatory surgery. J Clin Anesth. 1995;7:500–6.
20. Khan J, Liu M. Desflurane. In: StatPearls. Treasure Island: StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537106/.
21. Chaudhary K, Baghbarwal P, Wadhawan S. Anaesthesia for intellectually disabled. J Anaesthesiol Clin Pharmacol. 2017;33:432–40.
22. Jessop D. Pain in Down’s syndrome. Lancet. 2001;357:1041.
23. Malviya S, Voepel-Lewis T, Tat AR, Merkel S, Lauer A, Munro H, et al. Pain management in children with and without cognitive impairment following spine fusion surgery. Paediatr Anaesth. 2001;11:453–8.
24. Defrin R, Pick CG, Peretz C, Carmeli E. A quantitative somatosensory testing of pain threshold in individuals with mental retardation. Pain. 2004;108:58–66.
25. Gakhel B, Scott CS, MacIab AJ. Comparison of morphine requirements for sedation in Down’s syndrome and non-Down’s patients following paediatric cardiac surgery. Paediatr Anaesth. 1998;8:229–33.
26. Jackson I, McWhinnie D, Skues M. The pathway to success: management of the day surgical patient. London: British Association of Day Surgery; 2010.
27. Meitzner MC, Skumowicz JA. Anesthetic considerations for patients with Down syndrome. AANA J. 2005;73:103–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.